EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Community Acquired Pneumonia
Conditions
Community Acquired Pneumonia
Trial Timeline
Dec 1, 2005 → Jul 1, 2007
NCT ID
NCT00270517About EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days
EDP-420 / Duration of Treatment - 3 days + Telithromycin / Duration of Treatment - 7 days is a phase 2 stage product being developed by Enanta Pharmaceuticals for Community Acquired Pneumonia. The current trial status is unknown. This product is registered under clinical trial identifier NCT00270517. Target conditions include Community Acquired Pneumonia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00270517 | Phase 2 | UNKNOWN |
Competing Products
17 competing products in Community Acquired Pneumonia